Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 05 August 2021

Chair: Sabine Straus – Vice-Chair: Martin Huber
05 August 2021, 10:00 – 13:00, via teleconference

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1).
# Table of contents

1. **Introduction**  
   1.1. Welcome and declarations of interest of members, alternates and experts ............ 6  
   1.2. Agenda of the meeting on 05 August 2021 ......................................................... 6  
   1.3. Minutes of the previous meeting on 05-08 July 2021 ........................................ 6  

2. **EU referral procedures for safety reasons: urgent EU procedures**  
   2.1. Newly triggered procedures ................................................................. 6  
   2.2. Ongoing procedures ............................................................................. 6  
   2.3. Procedures for finalisation ................................................................. 6  

3. **EU referral procedures for safety reasons: other EU referral procedures**  
   3.1. Newly triggered procedures ................................................................. 6  
   3.2. Ongoing procedures ............................................................................. 7  
   3.3. Procedures for finalisation ................................................................. 7  
   3.4. Re-examination procedures ............................................................... 7  
   3.5. Others ................................................................................................. 7  

4. **Signals assessment and prioritisation**  
   4.1. New signals detected from EU spontaneous reporting systems ..................... 7  
   4.2. New signals detected from other sources .................................................. 7  
   4.3. Signals follow-up and prioritisation .......................................................... 7  
   4.4. Variation procedure(s) resulting from signal evaluation .............................. 7  

5. **Risk management plans (RMPs)**  
   5.1. Medicines in the pre-authorisation phase ....................................................... 7  
   5.2. Medicines in the post-authorisation phase – PRAC-led procedures .............. 8  
   5.3. Medicines in the post-authorisation phase – CHMP-led procedures ............ 8  

6. **Periodic safety update reports (PSURs)**  
   6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only ................................................................. 8  
   6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs) ................................................................. 8  
   6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only ................................................................. 8  
   6.4. Follow-up to PSUR/PSUSA procedures ......................................................... 8  
   6.5. Variation procedure(s) resulting from PSUSA evaluation ............................. 8  
   6.6. Expedited summary safety reviews ............................................................. 8
6.6.1. Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 002.6 ................................................................. 8
6.6.2. Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 011.5 ......................................................... 9
6.6.3. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/MEA 014.3 ........................................ 9
6.6.4. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 027.4 ...................................................... 9

7. Post-authorisation safety studies (PASS) 9

7.1. Protocols of PASS imposed in the marketing authorisation(s) .................................... 9
7.2. Protocols of PASS non-imposed in the marketing authorisation(s) ......................... 10
7.3. Results of PASS imposed in the marketing authorisation(s) .................................. 10
7.4. Results of PASS non-imposed in the marketing authorisation(s) ......................... 10
7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation ........................................ 10
7.6. Others ........................................................................................................... 10
7.7. New Scientific Advice ...................................................................................... 10
7.8. Ongoing Scientific Advice ................................................................................ 10
7.9. Final Scientific Advice (Reports and Scientific Advice letters) ........................... 10

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 10

8.1. Annual reassessments of the marketing authorisation ........................................ 10
8.2. Conditional renewals of the marketing authorisation .......................................... 11
8.3. Renewals of the marketing authorisation ............................................................ 11

9. Product related pharmacovigilance inspections 11

9.1. List of planned pharmacovigilance inspections .................................................... 11
9.2. Ongoing or concluded pharmacovigilance inspections ....................................... 11
9.3. Others ........................................................................................................... 11

10. Other safety issues for discussion requested by the CHMP or the EMA 11

10.1. Safety related variations of the marketing authorisation .................................... 11
10.2. Timing and message content in relation to Member States’ safety announcements 11
10.3. Other requests ............................................................................................ 11
10.4. Scientific Advice ......................................................................................... 11

11. Other safety issues for discussion requested by the Member States 12

11.1. Safety related variations of the marketing authorisation ................................ 12
11.2. Other requests .......................................................................................... 12
# 12. Organisational, regulatory and methodological matters

| 12.1. | Mandate and organisation of the PRAC | 12 |
| 12.2. | Coordination with EMA Scientific Committees or CMDh-v | 12 |
| 12.3. | Coordination with EMA Working Parties/Working Groups/Drafting Groups | 12 |
| 12.4. | Cooperation within the EU regulatory network | 12 |
| 12.5. | Cooperation with International Regulators | 12 |
| 12.6. | Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee | 12 |
| 12.7. | PRAC work plan | 12 |
| 12.8. | Planning and reporting | 12 |
| 12.9. | Pharmacovigilance audits and inspections | 13 |
| 12.9.1. | Pharmacovigilance systems and their quality systems | 13 |
| 12.9.2. | Pharmacovigilance inspections | 13 |
| 12.9.3. | Pharmacovigilance audits | 13 |
| 12.10. | Periodic safety update reports (PSURs) & Union reference date (EURD) list | 13 |
| 12.10.1. | Periodic safety update reports | 13 |
| 12.10.2. | Granularity and Periodicity Advisory Group (GPAG) | 13 |
| 12.10.3. | PSURs repository | 13 |
| 12.10.4. | Union reference date list – consultation on the draft list | 13 |
| 12.11. | Signal management | 13 |
| 12.12. | Adverse drug reactions reporting and additional reporting | 14 |
| 12.12.1. | Management and reporting of adverse reactions to medicinal products | 14 |
| 12.12.2. | Additional monitoring | 14 |
| 12.12.3. | List of products under additional monitoring – consultation on the draft list | 14 |
| 12.13. | EudraVigilance database | 14 |
| 12.13.1. | Activities related to the confirmation of full functionality | 14 |
| 12.13.2. | Coronavirus (COVID-19) pandemic – facilitating processing on individual case safety reports (ICSR) for COVID-19 vaccines | 14 |
| 12.14.1. | Risk management systems | 14 |
| 12.14.2. | Tools, educational materials and effectiveness measurement of risk minimisations | 14 |
| 12.15. | Post-authorisation safety studies (PASS) | 14 |
| 12.15.1. | Post-authorisation Safety Studies – imposed PASS | 14 |
| 12.15.2. | Post-authorisation Safety Studies – non-imposed PASS | 14 |
| 12.16. | Community procedures | 15 |
| 12.16.1. | Referral procedures for safety reasons | 15 |
| 12.17. | Renewals, conditional renewals, annual reassessments | 15 |
| 12.18. | Risk communication and transparency | 15 |
12.18.1. Public participation in pharmacovigilance .......................................................... 15
12.18.2. Safety communication ......................................................................................... 15

12.19. Continuous pharmacovigilance ............................................................................ 15
12.19.1. Incident management ......................................................................................... 15

12.20. Impact of pharmacovigilance activities ................................................................. 15
12.21. Others .................................................................................................................. 15

13. Any other business .................................................................................................... 15
14. Explanatory notes ...................................................................................................... 16
1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held on 05 August 2021. See August 2021 PRAC minutes (to be published post September 2021 PRAC meeting).

1.2. Agenda of the meeting on 05 August 2021

Action: For adoption

1.3. Minutes of the previous meeting on 05-08 July 2021

Action: For adoption in September 2021

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

None
3.2. Ongoing procedures
None

3.3. Procedures for finalisation
None

3.4. Re-examination procedures\(^1\)
None

3.5. Others
None

4. Signals assessment and prioritisation\(^2\)

4.1. New signals detected from EU spontaneous reporting systems
None

4.2. New signals detected from other sources
None

4.3. Signals follow-up and prioritisation
None

4.4. Variation procedure(s) resulting from signal evaluation
None

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase
None

---

\(^1\) Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
\(^2\) Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required.
5.2. **Medicines in the post-authorisation phase – PRAC-led procedures**

None

5.3. **Medicines in the post-authorisation phase – CHMP-led procedures**

None

6. **Periodic safety update reports (PSURs)**

6.1. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only**

None

6.2. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)**

None

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

None

6.4. **Follow-up to PSUR/PSUSA procedures**

None

6.5. **Variation procedure(s) resulting from PSUSA evaluation**

None

6.6. **Expeditied summary safety reviews\(^3\)**

6.6.1. **Coronavirus (COVID-19) mRNA\(^4\) vaccine (nucleoside-modified) - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 002.6**

Applicant: BioNTech Manufacturing GmbH
PRAC Rapporteur: Menno van der Elst; PRAC Co-rapporteur: Ulla Wändel Liminga
Scope: Seventh expedited monthly summary safety report (MSSR) for Comirnaty (COVID-

---

\(^3\) Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

\(^4\) Messenger ribonucleic acid
19 mRNA vaccine (nucleoside-modified)) during the coronavirus disease (COVID-19) pandemic

**Action:** For adoption of PRAC Assessment Report

### 6.6.2. Coronavirus (COVID-19) mRNA5 vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 011.5

**Applicant:** Moderna Biotech Spain, S.L.

**PRAC Rapporteur:** Hans Christian Siersted; **PRAC Co-rapporteur:** Brigitte Keller-Stanislawski

**Scope:** Sixth expedited monthly summary safety report (MSSR) for Spikevax (COVID-19 mRNA vaccine (nucleoside-modified)) during the coronavirus disease (COVID-19) pandemic

**Action:** For adoption of PRAC Assessment Report

### 6.6.3. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) – EMEA/H/C/005737/MEA 014.3

**Applicant:** Janssen-Cilag International N.V.

**PRAC Rapporteur:** Ulla Wändel Liminga; **PRAC Co-rapporteur:** Jean-Michel Dogné

**Scope:** Fourth expedited monthly summary safety report (MSSR) for COVID-19 Vaccine Janssen (COVID-19 vaccine (Ad26.COV2-S, recombinant)) during the coronavirus disease (COVID-19) pandemic

**Action:** For adoption of PRAC Assessment Report

### 6.6.4. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 027.4

**Applicant:** AstraZeneca AB

**PRAC Rapporteur:** Jean-Michel Dogné; **PRAC Co-rapporteur:** Maria del Pilar Rayon

**Scope:** Fifth expedited monthly summary safety report (MSSR) for Vaxzevria (COVID-19 vaccine (ChAdOx1-S [recombinant])) during the coronavirus disease (COVID-19) pandemic

**Action:** For adoption of PRAC Assessment Report

### 7. Post-authorisation safety studies (PASS)

#### 7.1. Protocols of PASS imposed in the marketing authorisation(s)6

None

---

5 Messenger ribonucleic acid
6 In accordance with Article 107n of Directive 2001/83/EC
7.2. Protocols of PASS non-imposed in the marketing authorisation(s)\(^7\)
None

7.3. Results of PASS imposed in the marketing authorisation(s)\(^8\)
None

7.4. Results of PASS non-imposed in the marketing authorisation(s)\(^9\)
None

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation
None

7.6. Others
None

7.7. New Scientific Advice
None

7.8. Ongoing Scientific Advice
None

7.9. Final Scientific Advice (Reports and Scientific Advice letters)
None

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation
None

\(^7\) In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

\(^8\) In accordance with Article 107p-q of Directive 2001/83/EC

\(^9\) In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
8.2. **Conditional renewals of the marketing authorisation**

None

8.3. **Renewals of the marketing authorisation**

None

9. **Product related pharmacovigilance inspections**

9.1. **List of planned pharmacovigilance inspections**

None

9.2. **Ongoing or concluded pharmacovigilance inspections**

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. **Others**

None

10. **Other safety issues for discussion requested by the CHMP or the EMA**

10.1. **Safety related variations of the marketing authorisation**

None

10.2. **Timing and message content in relation to Member States’ safety announcements**

None

10.3. **Other requests**

None

10.4. **Scientific Advice**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation
None

11.2. Other requests
None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC
None

12.2. Coordination with EMA Scientific Committees or CMDh-v
None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups
None

12.4. Cooperation within the EU regulatory network
None

12.5. Cooperation with International Regulators
None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee
None

12.7. PRAC work plan
None

12.8. Planning and reporting
None
12.9.  Pharmacovigilance audits and inspections

12.9.1.  Pharmacovigilance systems and their quality systems

None

12.9.2.  Pharmacovigilance inspections

None

12.9.3.  Pharmacovigilance audits

None

12.10.  Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1.  Periodic safety update reports

None

12.10.2.  Granularity and Periodicity Advisory Group (GPAG)

None

12.10.3.  PSURs repository

None

12.10.4.  Union reference date list – consultation on the draft list

None

12.11.  Signal management


None
12.12. **Adverse drug reactions reporting and additional reporting**

12.12.1. **Management and reporting of adverse reactions to medicinal products**

None

12.12.2. **Additional monitoring**

None

12.12.3. **List of products under additional monitoring – consultation on the draft list**

None

12.13. **EudraVigilance database**

12.13.1. **Activities related to the confirmation of full functionality**

None

12.13.2. **Coronavirus (COVID-19) pandemic – facilitating processing on individual case safety reports (ICSR) for COVID-19 vaccines**

**Action**: For discussion


12.14.1. **Risk management systems**

None

12.14.2. **Tools, educational materials and effectiveness measurement of risk minimisations**

None

12.15. **Post-authorisation safety studies (PASS)**

12.15.1. **Post-authorisation Safety Studies – imposed PASS**

None

12.15.2. **Post-authorisation Safety Studies – non-imposed PASS**

None
### 12.16. Community procedures

#### 12.16.1. Referral procedures for safety reasons

None

### 12.17. Renewals, conditional renewals, annual reassessments

None

### 12.18. Risk communication and transparency

#### 12.18.1. Public participation in pharmacovigilance

None

#### 12.18.2. Safety communication

None

### 12.19. Continuous pharmacovigilance

#### 12.19.1. Incident management

None

### 12.20. Impact of pharmacovigilance activities

None

### 12.21. Others

None

### 13. Any other business
14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.

The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.

The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.

RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/